Bianca Rocca: Beyond API-CAT – Who Should Continue Anticoagulation, And for How Long?
Bianca Rocca, Editor in Chief at European Heart Journal Cardiovascular Pharmacotherapy, shared on X about a recent article by Marcello Di Nisio and Tzu-Fei Wang, published in European Heart Journal – Cardiovascular Pharmacotherapy, adding:
“Beyond API-CAT: who should continue anticoagulation, and for how long?
API-CAT showed that reduced-dose apixaban preserves efficacy while reducing bleeding during extended anticoagulation for cancer-associated thrombosis. Yet, while it answers how intensely we should anticoagulate, two key questions remain: who should continue treatment and for how long?
In this Viewpoint, Marcello Di Nisio and Tzu-Fei Wang argues that extended anticoagulation should be a dynamic process of benefit-risk reassessment, adapting to cancer status, bleeding risk, prognosis and patients’ preferences.
The future may lie not only in safer doses, but in the right treatment, for the right patient, for the right duration.”
Title: Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis
Authors: Marcello Di Nisio, Tzu-Fei Wang

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines